The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin-modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β-emitting radionuclides, such as yttrium-90 and lutetium-177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio-treatment: [⁹⁰Y]Y-DOTATOC and [¹⁷⁷Lu]Lu-DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.

中文翻译：

---

90Y/177Lu-DOTATOC：从临床前研究到人体应用


PRRT（肽受体放射性核素疗法）对于无法手术或转移性神经内分泌肿瘤（NET）患者来说是一种很有前景的治疗方法。这些患者的无进展生存期（PFS）和总生存期（OS）与标准疗法相当。此类疗法的主角是生长抑素修饰的肽片段（[Tyr3]奥曲肽），配备有特定的螯合系统（DOTA），能够与β发射放射性核素（例如钇90和镥）形成稳定的键。 177.在这篇综述中，我们回顾了二十五年的文献，描述了两种最常用的 NET 放射治疗放射性药物的特性和性能：[ ⁹⁰ Y]Y-DOTATOC 和 [ ¹⁷⁷ Lu]Lu-DOTATOC 借此机会回顾决定其成功的最重要结果，将其从临床前研究推广到人类应用。